The risk of melanoma and hematologic cancers in patients with psoriasis - 18/04/17
Abstract |
Background |
The risk of melanoma and hematologic cancers in patients with psoriasis is controversial.
Objective |
We sought to assess the risk of melanoma and hematologic cancers in patients with psoriasis, and the association with different treatments.
Methods |
We used case-control and retrospective cohort designs to determine melanoma or hematologic cancer risk in patients with psoriasis. Risk with treatment type was assessed using Fisher exact test.
Results |
Patients with psoriasis had 1.53 times greater risk of developing a malignancy compared with patients without psoriasis (P < .01). There were no significant differences in malignancy risk among patients treated with topicals, phototherapy, systemics, or biologic agents. Patients with psoriasis and malignancy did not have significantly worse survival than patients without psoriasis.
Limitations |
It is possible that patients developed malignancy subsequent to the follow-up time included in the study.
Conclusion |
Patients with psoriasis may experience an elevated risk of melanoma and hematologic cancers, compared with the general population. The risk is not increased by systemic or biologic psoriasis therapies.
Le texte complet de cet article est disponible en PDF.Key words : biologic, hematologic cancer, malignancy, melanoma, phototherapy, psoriasis, topical therapy
Abbreviations used : CCI, CI, HR, IL, KPSC, PUVA, RA, RR, TNF, TNFi, UV
Plan
| Funding sources: None. |
|
| Disclosure: Dr Wu received research funding from AbbVie, Amgen, AstraZeneca, Coherus Biosciences, Dermira, Eli Lilly, Janssen, Merck, Novartis, Pfizer, Regeneron, Sandoz, and Sun Pharmaceutical Industries; he is a consultant for AbbVie, Amgen, Celgene, Dermira, Eli Lilly, Pfizer, Regeneron, and Sun Pharmaceutical Industries. Ms Reddy and Dr Martires have no conflicts of interest to declare. |
|
| Supplemental materials are available at www.jaad.org/. |
Vol 76 - N° 4
P. 639 - avril 2017 Retour au numéro
Article précédent
- Malignancy rates in a large cohort of patients with systemically treated psoriasis in a managed care population
- Maryam M. Asgari, G. Thomas Ray, Jamie L. Geier, Charles P. Quesenberry
- Lesions on the back of hands and female gender predispose to stigmatization in patients with psoriasis
- Marlena Hawro, Marcus Maurer, Karsten Weller, Romuald Maleszka, Anna Zalewska-Janowska, Andrzej Kaszuba, Zofia Gerlicz-Kowalczuk, Tomasz Hawro
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?